Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Incomplete Response in Late Life Depression: Getting to Remission
Brief Summary: The primary aims of this study are to:

1. Assess the efficacy of aripiprazole augmentation for the acute and continuation treatment of TRLLD.

   Hypothesis 1: Patients with TRLLD (defined as those who do not remit after 12 weeks of acute treatment with venlafaxine XR) will have a higher rate of remission with aripiprazole than with placebo augmentation (primary outcome) and greater improvement in depressive symptoms and stability of remission (secondary outcomes).
2. Assess the tolerability of aripiprazole in TRLLD with a focus on adiposity and akathisia/restlessness.

Hypothesis 2: Aripiprazole will be associated with a higher rate of clinically significant akathisia and increased adiposity than placebo.

The Secondary/exploratory aims of this study are to:

1. Examine anxiety, medical burden, and executive impairment as moderators of aripiprazole augmentation efficacy in TRLLD.

   Hypothesis 3: Pre-levels of anxiety symptoms, medical burden, and executive impairment will be treatment-specific factors: they will moderate the efficacy of aripiprazole augmentation. The aripiprazole-placebo difference will be greater in individuals with these variables, compared to those without these variables because these three factors will be associated with a decreased likelihood that "staying the course" with venlafaxine monotherapy will achieve remission.
2. Examine genetic predictors (phase 1) and moderators (phase 2-3) of treatment outcomes, while controlling for drug exposure.

Hypothesis 4: Selected polymorphisms will reduce remission rate with venlafaxine and will reduce efficacy and tolerability with aripiprazole.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole (Fixed dose) | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aripiprazole (Titrated dose) | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aripiprazole (Fixed dose); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Aripiprazole (Titrated dose); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: 1: venlafaxine plus aripiprazole; Type: EXPERIMENTAL; Interventions: Drug: venlafaxine XR plus aripiprazole | Arm Label: 2: Placebo Comparator; Type: EXPERIMENTAL; Interventions: Drug: venlafaxine plus placebo | Intervention Type: DRUG; Name: venlafaxine XR plus aripiprazole; Assigned to Arm(s): 1: venlafaxine plus aripiprazole | Intervention Type: DRUG; Name: venlafaxine plus placebo; Assigned to Arm(s): 2: Placebo Comparator
C: Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A
D: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A

Answer: B